RBC reiterates Intel stock rating on AI demand, foundry progress

On October 25, 2026, RBC and Oppenheimer analysts issued updates on two major stocks. RBC reiterated its rating on Intel stock, citing demand for artificial intelligence and progress in its foundry business. According to RBC, Intel's position in these areas is a key factor in its rating.

Separately, Oppenheimer analysts also reiterated their rating on Amgen stock. This decision was influenced by recent data on one of Amgen's cancer drugs. The specifics of the data and the rating itself have not been detailed in the reports.

These updates from RBC and Oppenheimer provide insights into the factors currently influencing their assessments of Intel and Amgen. The analysts' focus on AI demand, foundry progress, and cancer drug data indicates these areas are significant for the companies' stock performance.

Further details about the ratings, such as their implications for the stocks' future performance, have not been reported yet. Investors and analysts will likely continue to monitor Intel and Amgen's progress in AI, foundry operations, and cancer drug development for future insights.